Suppr超能文献

老年患者的 IgA 肾病。

IgA Nephropathy in Elderly Patients.

机构信息

Department of Nephrology, Hospital Universitario 12 de Octubre, Madrid, Spain.

Department of Medicine, Complutense University, Madrid, Spain.

出版信息

Clin J Am Soc Nephrol. 2019 Aug 7;14(8):1183-1192. doi: 10.2215/CJN.13251118. Epub 2019 Jul 16.

Abstract

BACKGROUND AND OBJECTIVES

Some studies suggest that the incidence of IgA nephropathy is increasing in older adults, but there is a lack of information about the epidemiology and behavior of the disease in that age group.

DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: In this retrospective multicentric study, we analyzed the incidence, forms of presentation, clinical and histologic characteristics, treatments received, and outcomes in a cohort of 151 patients ≥65 years old with biopsy-proven IgA nephropathy diagnosed between 1990 and 2015. The main outcome was a composite end point of kidney replacement therapy or death before kidney replacement therapy.

RESULTS

We found a significant increase in the diagnosis of IgA nephropathy over time from six patients in 1990-1995 to 62 in 2011-2015 ( value for trend =0.03). After asymptomatic urinary abnormalities (84 patients; 55%), AKI was the most common form of presentation (61 patients; 40%). Within the latter, 53 (86%) patients presented with hematuria-related AKI (gross hematuria and tubular necrosis associated with erythrocyte casts as the most important lesions in kidney biopsy), and eight patients presented with crescentic IgA nephropathy. Six (4%) patients presented with nephrotic syndrome. Among hematuria-related AKI, 18 (34%) patients were receiving oral anticoagulants, and this proportion rose to 42% among the 34 patients older than 72 years old who presented with hematuria-related AKI. For the whole cohort, survival rates without the composite end point were 74%, 48%, and 26% at 1, 2, and 5 years, respectively. Age, serum creatinine at presentation, and the degree of interstitial fibrosis in kidney biopsy were risk factors significantly associated with the outcome, whereas treatment with renin-angiotensin-aldosterone blockers was associated with a lower risk. Immunosuppressive treatments were not significantly associated with the outcome.

CONCLUSIONS

The diagnosis of IgA nephropathy among older adults in Spain has progressively increased in recent years, and anticoagulant therapy may be partially responsible for this trend. Prognosis was poor.

PODCAST

This article contains a podcast at https://www.asn-online.org/media/podcast/CJASN/2019_07_16_CJASNPodcast_19_08_.mp3.

摘要

背景和目的

一些研究表明,IgA 肾病在老年人中的发病率正在增加,但关于该年龄段疾病的流行病学和表现形式,我们知之甚少。

设计、地点、参与者和测量方法:在这项回顾性多中心研究中,我们分析了 1990 年至 2015 年间确诊为活检证实的 IgA 肾病且年龄≥65 岁的 151 例患者的发病率、表现形式、临床和组织学特征、接受的治疗和结局。主要结局是肾脏替代治疗或肾脏替代治疗前死亡的复合终点。

结果

我们发现随着时间的推移,IgA 肾病的诊断显著增加,从 1990-1995 年的 6 例增加到 2011-2015 年的 62 例(趋势值=0.03)。在无症状性尿异常(84 例;55%)之后,急性肾损伤(AKI)是最常见的表现形式(61 例;40%)。在后者中,53 例(86%)患者表现为血尿相关 AKI(肉眼血尿和肾小管坏死,伴有红细胞管型,是肾脏活检中最重要的病变),8 例患者表现为新月体 IgA 肾病。6 例(4%)患者表现为肾病综合征。在血尿相关 AKI 中,18 例(34%)患者正在接受口服抗凝剂,而在 34 例年龄>72 岁且表现为血尿相关 AKI 的患者中,这一比例上升至 42%。对于整个队列,无复合终点的生存率分别为 74%、48%和 26%,在 1、2 和 5 年时。年龄、就诊时的血清肌酐和肾脏活检中的间质纤维化程度是与结局显著相关的危险因素,而肾素-血管紧张素-醛固酮阻滞剂的治疗与较低的风险相关。免疫抑制治疗与结局无显著相关性。

结论

近年来,西班牙老年人群中 IgA 肾病的诊断逐渐增加,抗凝治疗可能是导致这种趋势的部分原因。预后不佳。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/8b31/6682823/2246661ae961/CJN.13251118absf1.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验